{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:59Z","timestamp":1786980539584,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006062","name":"Foundation for Promotion of Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10147-017-1200-4","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T07:06:21Z","timestamp":1508137581000},"page":"382-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A double-blind randomized phase II dose-finding study of olanzapine 10\u00a0mg or 5\u00a0mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy"],"prefix":"10.1007","volume":"23","author":[{"given":"Takako","family":"Yanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Ohyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Terakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198. doi:\n                        10.1200\/JCO.2010.34.4614","journal-title":"J Clin Oncol"},{"key":"1200_CR2","unstructured":"National Comprehensive Cancer Network (2014) Antiemesis. In: NCCN clinical practice guidelines in oncology version 1. 2014. Available via the National Comprehensive Cancer Network. \n                        https:\/\/www.nccn.org\/\n                        \n                    . Accessed 13 Sep 2014"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601\u20131606. doi:\n                        10.1093\/annonc\/mdw220","journal-title":"Ann Oncol"},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396. doi:\n                        10.1016\/0893-133X(94)00129-N","journal-title":"Neuropsychopharmacology"},{"key":"1200_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57\u201373","journal-title":"Psychopharmacology (Berl)"},{"key":"1200_CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","volume":"37","author":"FP Bymaster","year":"1999","unstructured":"Bymaster FP, Nelson DL, DeLapp NW et al (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107\u2013122","journal-title":"Schizophr Res"},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari RM, Einhorn LH, Passik SD et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529\u2013534. doi:\n                        10.1007\/s00520-004-0755-6","journal-title":"Support Care Cancer"},{"key":"1200_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285\u20131291. doi:\n                        10.1007\/s00520-007-0248-5","journal-title":"Support Care Cancer"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131. doi:\n                        10.1186\/1756-9966-28-131","journal-title":"J Exp Clin Cancer Res"},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195. doi:\n                        10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663. doi:\n                        10.1007\/s00520-012-1710-6","journal-title":"Support Care Cancer"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47:542\u2013550. doi:\n                        10.1016\/j.jpainsymman.2013.05.003","journal-title":"J Pain Symptom Manag"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24:675\u2013682. doi:\n                        10.1007\/s00520-015-2829-z","journal-title":"Support Care Cancer"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jjco\/hyu191","volume":"45","author":"K Nagashima","year":"2015","unstructured":"Nagashima K, Iwasa S, Yanai T et al (2015) A double-blind randomized Phase II study of olanzapine 10 versus 5\u00a0mg for emesis induced by highly emetogenic chemotherapy. Jpn J Clin Oncol 45:229\u2013231. doi:\n                        10.1093\/jjco\/hyu191","journal-title":"Jpn J Clin Oncol"},{"key":"1200_CR15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.4780140924","volume":"14","author":"B Lecoutre","year":"1995","unstructured":"Lecoutre B, Derzko G, Grouin JM (1995) Bayesian predictive approach for inference about proportions. Stat Med 14:1057\u20131063","journal-title":"Stat Med"},{"key":"1200_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1081\/CNV-200029066","volume":"22","author":"SD Passik","year":"2004","unstructured":"Passik SD, Navari RM, Jong SH (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 22:383\u2013388","journal-title":"Cancer Invest"},{"issue":"suppl 5","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133. doi:\n                        10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142. doi:\n                        10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"1200_CR19","unstructured":"National comprehensive cancer network (2017) Antiemesis. In: NCCN clinical practice guidelines in oncology version 1. 2017-February 22, 2017. Available via the National comprehensive cancer network. \n                        https:\/\/www.nccn.org\/\n                        \n                    . Accessed 23 Mar 2017"},{"issue":"15","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"10111","DOI":"10.1200\/JCO.2016.34.15_suppl.10111","volume":"34","author":"H Hashimoto","year":"2016","unstructured":"Hashimoto H, Yanai T, Nagashima K et al (2016) A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. J Clin Oncol 34(15):10111. doi:\n                        10.1200\/JCO.2016.34.15_suppl.10111","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T04:30:47Z","timestamp":1522729847000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1200-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}